NDAORAL-28TABLET
Approved
Aug 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OVCON-50 (ethinyl estradiol; norethindrone) by AbbVie. Approved for pregnancy. First approved in 1975.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OVCON-50 is an oral combined hormonal contraceptive containing ethinyl estradiol and norethindrone, approved in 1975 as an NDA by AbbVie. It prevents pregnancy through estrogen and progestin receptor agonism. This product is a foundational member of the oral contraceptive class with decades of clinical use.
LOE Approaching
As a legacy oral contraceptive approaching loss of exclusivity with minimal current spending data, the brand team is likely small and focused on managed care and generic transition strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on OVCON-50 as a legacy AbbVie product offers limited growth trajectory and modest visibility compared to pipeline assets, but provides exposure to mature market dynamics, managed care strategy, and generic transition planning. Roles are likely focused on defending market share against generics and alternative modalities rather than innovation.
Brand Manager
Worked on OVCON-50 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.